Fresh Tracks Therapeutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Fresh Tracks Therapeutics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Brickell Biotech changes name to Fresh Tracks Therapeutics
Sep 07Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M
Aug 11Brickell Biotech regains Nasdaq compliance for minimum bid price requirement
Jul 20Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely
Feb 14
Brickell Biotech Advances To Phase III As It Eyes Commercialization
May 10Brickell Biotech completes patient enrollment in late-stage sweat disorder study
Apr 27Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.
Jan 06
Brickell Biotech (BBI) Investor Presentation - Slideshow
Dec 02Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26
Nov 18In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Fresh Tracks Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | 8 | -6 | -4 | -4 | N/A |
| 9/30/2023 | 10 | -9 | -6 | -6 | N/A |
| 6/30/2023 | 3 | -17 | -13 | -13 | N/A |
| 3/31/2023 | 7 | -16 | -14 | -14 | N/A |
| 12/31/2022 | 7 | -21 | -19 | -19 | N/A |
| 9/30/2022 | 5 | -23 | -22 | -22 | N/A |
| 6/30/2022 | 5 | -30 | -28 | -28 | N/A |
| 3/31/2022 | 0 | -40 | -40 | -40 | N/A |
| 12/31/2021 | 0 | -39 | -36 | -36 | N/A |
| 9/30/2021 | 0 | -41 | -36 | -36 | N/A |
| 6/30/2021 | 0 | -32 | -29 | -29 | N/A |
| 3/31/2021 | 1 | -26 | -19 | -19 | N/A |
| 12/31/2020 | 2 | -21 | -20 | -20 | N/A |
| 9/30/2020 | 2 | -24 | -29 | -29 | N/A |
| 6/30/2020 | 4 | -25 | -38 | -38 | N/A |
| 3/31/2020 | 5 | -24 | -37 | -37 | N/A |
| 12/31/2019 | 8 | -14 | -36 | -36 | N/A |
| 9/30/2019 | 10 | -7 | -26 | -26 | N/A |
| 6/30/2019 | 12 | -6 | -19 | -19 | N/A |
| 3/31/2019 | 9 | -7 | -4 | -4 | N/A |
| 12/31/2018 | 11 | -15 | 4 | 4 | N/A |
| 12/31/2017 | 8 | -23 | -9 | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if FRTX's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if FRTX's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if FRTX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if FRTX's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if FRTX's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FRTX's Return on Equity is forecast to be high in 3 years time